JP2019532041A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019532041A5 JP2019532041A5 JP2019512835A JP2019512835A JP2019532041A5 JP 2019532041 A5 JP2019532041 A5 JP 2019532041A5 JP 2019512835 A JP2019512835 A JP 2019512835A JP 2019512835 A JP2019512835 A JP 2019512835A JP 2019532041 A5 JP2019532041 A5 JP 2019532041A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- formula
- compound
- substituted
- phenyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000217 alkyl group Chemical group 0.000 claims description 129
- 150000001875 compounds Chemical class 0.000 claims description 58
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 38
- 238000000034 method Methods 0.000 claims description 27
- 102000004169 proteins and genes Human genes 0.000 claims description 24
- 108090000623 proteins and genes Proteins 0.000 claims description 24
- 125000003545 alkoxy group Chemical group 0.000 claims description 23
- 229910052739 hydrogen Inorganic materials 0.000 claims description 22
- 229910052799 carbon Inorganic materials 0.000 claims description 21
- 125000001424 substituent group Chemical group 0.000 claims description 15
- 125000005647 linker group Chemical group 0.000 claims description 13
- 125000003118 aryl group Chemical group 0.000 claims description 12
- 229910052794 bromium Inorganic materials 0.000 claims description 12
- 229910052801 chlorine Inorganic materials 0.000 claims description 12
- 229910052740 iodine Inorganic materials 0.000 claims description 12
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 11
- 229940079593 drug Drugs 0.000 claims description 10
- 239000003814 drug Substances 0.000 claims description 10
- 229910052736 halogen Inorganic materials 0.000 claims description 10
- 150000002367 halogens Chemical class 0.000 claims description 10
- 125000001072 heteroaryl group Chemical group 0.000 claims description 10
- 229910052760 oxygen Inorganic materials 0.000 claims description 10
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims description 8
- 108091034117 Oligonucleotide Proteins 0.000 claims description 8
- 125000001931 aliphatic group Chemical group 0.000 claims description 8
- 150000001413 amino acids Chemical class 0.000 claims description 8
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 8
- 229910052731 fluorine Inorganic materials 0.000 claims description 8
- 239000002773 nucleotide Substances 0.000 claims description 8
- 125000003729 nucleotide group Chemical group 0.000 claims description 8
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 claims description 7
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 7
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 7
- 150000004676 glycans Chemical class 0.000 claims description 6
- 229920000642 polymer Polymers 0.000 claims description 6
- 229920001282 polysaccharide Polymers 0.000 claims description 6
- 239000005017 polysaccharide Substances 0.000 claims description 6
- SJQRQOKXQKVJGJ-UHFFFAOYSA-N 5-(2-aminoethylamino)naphthalene-1-sulfonic acid Chemical compound C1=CC=C2C(NCCN)=CC=CC2=C1S(O)(=O)=O SJQRQOKXQKVJGJ-UHFFFAOYSA-N 0.000 claims description 5
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 5
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 5
- 125000002373 5 membered heterocyclic group Chemical group 0.000 claims description 4
- 125000004070 6 membered heterocyclic group Chemical group 0.000 claims description 4
- 125000000304 alkynyl group Chemical group 0.000 claims description 4
- 229940059260 amidate Drugs 0.000 claims description 4
- -1 antibodies Chemical class 0.000 claims description 4
- 150000001540 azides Chemical class 0.000 claims description 4
- 229960002685 biotin Drugs 0.000 claims description 4
- 235000020958 biotin Nutrition 0.000 claims description 4
- 239000011616 biotin Substances 0.000 claims description 4
- NPUKDXXFDDZOKR-LLVKDONJSA-N etomidate Chemical compound CCOC(=O)C1=CN=CN1[C@H](C)C1=CC=CC=C1 NPUKDXXFDDZOKR-LLVKDONJSA-N 0.000 claims description 4
- 125000005842 heteroatom Chemical group 0.000 claims description 4
- 125000000623 heterocyclic group Chemical group 0.000 claims description 4
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 4
- 235000000346 sugar Nutrition 0.000 claims description 4
- 150000008163 sugars Chemical class 0.000 claims description 4
- 150000003573 thiols Chemical class 0.000 claims description 4
- 229910052717 sulfur Inorganic materials 0.000 claims description 3
- IYMAXBFPHPZYIK-BQBZGAKWSA-N Arg-Gly-Asp Chemical compound NC(N)=NCCC[C@H](N)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(O)=O IYMAXBFPHPZYIK-BQBZGAKWSA-N 0.000 claims description 2
- GAWIXWVDTYZWAW-UHFFFAOYSA-N C[CH]O Chemical group C[CH]O GAWIXWVDTYZWAW-UHFFFAOYSA-N 0.000 claims description 2
- 102000004190 Enzymes Human genes 0.000 claims description 2
- 108090000790 Enzymes Proteins 0.000 claims description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 2
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 2
- 238000006243 chemical reaction Methods 0.000 claims description 2
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 2
- 108010045325 cyclic arginine-glycine-aspartic acid peptide Proteins 0.000 claims description 2
- 239000001257 hydrogen Substances 0.000 claims description 2
- 150000002772 monosaccharides Chemical class 0.000 claims description 2
- 238000006467 substitution reaction Methods 0.000 claims description 2
- 230000002285 radioactive effect Effects 0.000 claims 2
- 239000000562 conjugate Substances 0.000 description 9
- 239000000427 antigen Substances 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 239000000611 antibody drug conjugate Substances 0.000 description 2
- 229940049595 antibody-drug conjugate Drugs 0.000 description 2
- 125000004076 pyridyl group Chemical group 0.000 description 2
- 229960005395 cetuximab Drugs 0.000 description 1
- 125000003636 chemical group Chemical group 0.000 description 1
- 229960000575 trastuzumab Drugs 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023007868A JP2023055766A (ja) | 2016-09-01 | 2023-01-23 | アルケンホスホンアミデートまたはアルキンホスホンアミデートとの化学選択的チオールコンジュゲーション |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16001917 | 2016-09-01 | ||
| EP16001917.0 | 2016-09-01 | ||
| PCT/EP2017/071937 WO2018041985A1 (en) | 2016-09-01 | 2017-09-01 | Chemoselective thiol-conjugation with alkene or alkyne-phosphonamidates |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023007868A Division JP2023055766A (ja) | 2016-09-01 | 2023-01-23 | アルケンホスホンアミデートまたはアルキンホスホンアミデートとの化学選択的チオールコンジュゲーション |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019532041A JP2019532041A (ja) | 2019-11-07 |
| JP2019532041A5 true JP2019532041A5 (enExample) | 2020-10-01 |
| JP7217225B2 JP7217225B2 (ja) | 2023-02-02 |
Family
ID=56888890
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019512835A Active JP7217225B2 (ja) | 2016-09-01 | 2017-09-01 | アルケンホスホンアミデートまたはアルキンホスホンアミデートとの化学選択的チオールコンジュゲーション |
| JP2023007868A Pending JP2023055766A (ja) | 2016-09-01 | 2023-01-23 | アルケンホスホンアミデートまたはアルキンホスホンアミデートとの化学選択的チオールコンジュゲーション |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023007868A Pending JP2023055766A (ja) | 2016-09-01 | 2023-01-23 | アルケンホスホンアミデートまたはアルキンホスホンアミデートとの化学選択的チオールコンジュゲーション |
Country Status (7)
| Country | Link |
|---|---|
| US (4) | US11161873B2 (enExample) |
| EP (1) | EP3506949A1 (enExample) |
| JP (2) | JP7217225B2 (enExample) |
| CN (2) | CN117903297A (enExample) |
| AU (1) | AU2017320913B2 (enExample) |
| CA (1) | CA3032251A1 (enExample) |
| WO (1) | WO2018041985A1 (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2019232602B2 (en) * | 2018-03-07 | 2025-03-27 | Forschungsverbund Berlin E.V. | Chemoselective thiol-conjugation with alkene or alkyne-phosphonothiolates and -phosphonates |
| CN109666044B (zh) * | 2018-07-04 | 2021-03-05 | 浙江大学 | 基于[2.2]对环芳烷骨架的有机磷化合物及其中间体和制备方法与用途 |
| CN115697331A (zh) * | 2019-11-22 | 2023-02-03 | 加利福尼亚大学董事会 | Taspase1抑制剂及其用途 |
| WO2021263087A2 (en) * | 2020-06-26 | 2021-12-30 | Yale University | Compositions and methods for selective detection and/or inhibition of bacterial pathogens in microbial communities |
| US20250269046A1 (en) | 2021-02-26 | 2025-08-28 | Forschungsverbund Berlin E.V. | Cellular uptake of large biomolecules enabled by cell-surface-reactive cell-penetrating peptide additives |
| CN117545511A (zh) | 2021-04-23 | 2024-02-09 | 柏林合作研究学会 | 与不饱和磷(v)化合物的硫醇偶联 |
| IL312675A (en) | 2021-11-09 | 2024-07-01 | Tubulis Gmbh | Conjugates involving phosphorus (V) and a drug component |
| IL312677A (en) | 2021-11-09 | 2024-07-01 | Tubulis Gmbh | Conjugates including phosphorus (V) and a camptothecin component |
| US20250049939A1 (en) | 2021-12-10 | 2025-02-13 | Tubulis Gmbh | Novel flt3 antibodies and antibody-drug-conjugates based thereon, therapeutic methods and uses thereof in combination with tyrosine kinase inhibitors |
| CN119451970A (zh) | 2022-06-27 | 2025-02-14 | 埃维克斯塔生物公司 | 用于治疗癌症的n-取代的吲哚衍生物及其偶联物 |
| CN120112312A (zh) | 2022-10-18 | 2025-06-06 | Tubulis 股份有限公司 | 新型抗-tpbg抗体和基于其的抗体-药物偶联物、其治疗方法及用途 |
| JP2025536308A (ja) | 2022-10-18 | 2025-11-05 | テューブリス ゲーエムベーハー | 新規なＮａＰｉ２ｂ抗体を有する新規な抗体－薬物コンジュゲート、治療的方法、ならびにそれらの使用 |
| CN120166939A (zh) | 2022-10-18 | 2025-06-17 | Tubulis 股份有限公司 | 新型抗napi2b抗体和基于该抗体的抗体-药物-偶联物、治疗方法及其用途 |
| IL321506A (en) | 2022-12-22 | 2025-08-01 | Tubulis Gmbh | Conjugates comprising a phosphorus(v) moiety and a drug |
| WO2025046090A1 (en) | 2023-09-01 | 2025-03-06 | Tubulis Gmbh | Methods of preparing phosphonamidate compounds |
| WO2025146313A1 (en) | 2024-01-04 | 2025-07-10 | Deutsches Krebsforschungszentrum | Phosphinites as reductive disulfide rebridging agents |
| US20250269052A1 (en) | 2024-02-27 | 2025-08-28 | Bristol-Myers Squibb Company | Anti-ceacam5 antibody drug conjugates |
| CN119391070A (zh) * | 2024-11-28 | 2025-02-07 | 宁波卡倍亿新材料科技有限公司 | 一种新能源汽车耐高温阻燃电缆料及其制备方法 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2535174A (en) | 1949-04-07 | 1950-12-26 | Us Rubber Co | Mercaptoethanephosphonates |
| DE2024250A1 (de) * | 1970-05-19 | 1971-12-02 | Farbwerke Hoechst AG, vorm. Meister Lucius & Brüning, 6000 Frankfurt | Antimikrobielle grenzflächenaktive Mittel |
| ES2176484T3 (es) | 1995-08-18 | 2002-12-01 | Morphosys Ag | Bancos de proteinas/(poli)peptidos. |
| US9023834B2 (en) * | 2008-11-13 | 2015-05-05 | Taigen Biotechnology Co., Ltd. | Lyophilization formulation |
| CN102058547A (zh) * | 2009-11-12 | 2011-05-18 | 太景生物科技股份有限公司 | 冻干制剂 |
| EP2916872B1 (en) * | 2012-11-09 | 2019-02-27 | Innate Pharma | Recognition tags for tgase-mediated conjugation |
| JP2016538877A (ja) | 2013-10-14 | 2016-12-15 | シンアフィックス ビー．ブイ． | 修飾糖タンパク質、タンパク質コンジュゲート及びそれらの調製方法 |
| JP2017520617A (ja) | 2014-05-09 | 2017-07-27 | バイエル・ファルマ・アクティエンゲゼルシャフト | システインアミノ酸の対ｃ２架橋によるペプチドおよびタンパク質の標的複合化のための工程 |
-
2017
- 2017-09-01 JP JP2019512835A patent/JP7217225B2/ja active Active
- 2017-09-01 EP EP17772314.5A patent/EP3506949A1/en active Pending
- 2017-09-01 CN CN202311230447.3A patent/CN117903297A/zh active Pending
- 2017-09-01 CA CA3032251A patent/CA3032251A1/en active Pending
- 2017-09-01 CN CN201780053946.6A patent/CN109689112B/zh active Active
- 2017-09-01 AU AU2017320913A patent/AU2017320913B2/en active Active
- 2017-09-01 US US16/328,199 patent/US11161873B2/en active Active
- 2017-09-01 WO PCT/EP2017/071937 patent/WO2018041985A1/en not_active Ceased
-
2021
- 2021-08-30 US US17/460,791 patent/US11746124B2/en active Active
-
2023
- 2023-01-23 JP JP2023007868A patent/JP2023055766A/ja active Pending
- 2023-07-10 US US18/349,727 patent/US12171837B2/en active Active
-
2024
- 2024-11-26 US US18/960,256 patent/US20250090672A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019532041A5 (enExample) | ||
| Kelly et al. | Self-assembling influenza nanoparticle vaccines drive extended germinal center activity and memory B cell maturation | |
| ES2565481T3 (es) | Anticuerpo anti-PlGF novedoso | |
| JP2015518479A5 (enExample) | ||
| KR102056932B1 (ko) | 메디토프와 메디토프-결합 항체 및 이들의 용도 | |
| KR102811956B1 (ko) | 암을 치료하기 위한 1-(피페리디노카보닐메틸)-2-옥소피페라진 유도체 | |
| CN109715662A (zh) | 使用抑胃肽受体(gipr)结合蛋白与glp-1激动剂的组合来治疗或改善代谢病症的方法 | |
| WO2014206304A1 (zh) | 高稳定性的t细胞受体及其制法和应用 | |
| RU2013128361A (ru) | Her2-связывающие белки, меченые комплексом 18f-фторида алюминия и nota | |
| JP2007524677A (ja) | 放射性標識化合物及び組成物、それらの前駆体及びそれらの製造方法 | |
| CN113710688A (zh) | 用于治疗血液癌症和实体瘤癌症的嵌合抗原受体修饰的t细胞(car-t) | |
| KR20200014780A (ko) | 최적화된 핵산 항체 작제물 | |
| JP2017533886A5 (enExample) | ||
| JP2015504893A5 (enExample) | ||
| JP2010527922A5 (enExample) | ||
| JP2015517577A5 (enExample) | ||
| CN114438088A (zh) | 一种溶酶体靶向的核酸嵌合体的制备及应用 | |
| JPWO2020206330A5 (enExample) | ||
| JPWO2019170710A5 (enExample) | ||
| Lau et al. | Evolution and protein packaging of small-molecule RNA aptamers | |
| JP2010517544A5 (enExample) | ||
| JP2023169422A (ja) | 結合ポリペプチドおよびそれを作製する方法 | |
| CN110049775A (zh) | 用作疫苗的表达外泌体锚定蛋白的核苷酸序列 | |
| Aoki et al. | Mirror-image single-domain antibody for a novel nonimmunogenic drug scaffold | |
| CN101531718B (zh) | 抗VEGFR-2抗体嵌合Fab抗体片段及其制备方法、应用 |